HIV/AIDS
Reports outline HIV/AIDS research from J.V.R. Madruga and colleagues
Published in AIDS Weekly, February 4th, 2008
According to a study from the United States, "Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC) and efavirenz (EFV), and an ongoing 336-week open-label extension phase. Patients in 3 countries completing the d4T treatment phase were allowed to switch d4T to TDF and receive once-daily TDF+3TC+EFV in the extension phase."
"At the time of switch, 100% and 99% of patients (n = 85; 60% male, 64% White; mean age 37 years; mean CD4 = 650 celIS/MM3) had HIV RNA < 400 and < 50 copies/mL. At 144 weeks after the switch, 89% (missing = failure) had HIV RNA < 400...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-02-04)
More Articles from AIDS Weekly
- Cancer Vaccines
Newly discovered virus linked to deadly skin cancer - Clinical Trial Research
Studies from Boehringer Ingelheim GmbH provide new data on clinical trial research - HIV/AIDS
New HIV/AIDS study results from N. Gupte et al described - HIV/AIDS
Reports outline HIV/AIDS research from Cornell University - HIV/AIDS
Reports summarize HIV/AIDS study results from V.J. Sekar and co-researchers - HIV/AIDS
Research from Emory University, Medical Department in HIV/AIDS provides new insights - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
